Discussion on "Predictively consistent prior effective sample sizes," by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan.

We extend the approach of finding effective sample size for a typical phase II clinical trial having efficacy and toxicity as two components of the response vector. The case of binary efficacy and binary toxicity is illustrated under Dirichlet and multivariate T priors.